Iran Flu Diagnostic and Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type Of Flu (Type A, Type B), By Offering (Diagnostics (Rapid Influenza Diagnostic Test, Rapid Molecular Assay, Others), Therapeutics), By Age Group (0-14 Years, 15-64 Years, >=65 Years), And By End-User (Hospital Laboratory, Outpatient Clinic, Reference Laboratory) - Forecasts From 2022 To 2027

Description

The Iranian flu diagnostic and treatment market is projected to grow at a CAGR of 5.36% throughout the forecast period and reach a market value of US$324.156 million by 2027. The market was valued at US$224.897 million in 2020.

Key Highlights

• Government Procurement Drives Therapeutics Demand: The centralised public health infrastructure, managed by the Ministry of Health and Medical Education (MoHME), ensures the strategic stocking and distribution of antiviral drugs, primarily Oseltamivir, directly fueling persistent, high-volume demand in the Therapeutics segment.
• Shift to Molecular Diagnostics in Major Centres: The established Hospital Laboratory and Reference Laboratory network has integrated molecular techniques, specifically multiplex real-time PCR, to differentiate influenza from other respiratory pathogens, a factor that increases demand for advanced Rapid Molecular Assay kits over traditional Rapid Influenza Diagnostic Tests (RIDTs).
• High Burden of Influenza A Shapes Diagnostics and Treatment: Epidemiological data consistently demonstrate that Type A is the most prevalent and often most severe influenza type, particularly H1N1, which channels the majority of diagnostic demand toward Type A detection and dictates the treatment protocol (e.g., Oseltamivir administration) across the >=65 Years and high-risk patient groups.
• Sanctions Impose Constraints on Imported Technology: International sanctions fundamentally restrict access to and increase the cost of sophisticated diagnostic equipment and certain imported pharmaceutical Active Pharmaceutical Ingredients (APIs), thereby stimulating and concentrating demand toward domestically produced kits and generic antiviral formulations from Iranian knowledge-based companies.

The Iran Flu Diagnostic and Treatment Market is a strategic, publicly-managed segment of the national healthcare system, focused on mitigating the recurrent, high seasonal burden of influenza. The market encompasses both laboratory assays for pathogen identification and the pharmacological interventions designed to reduce morbidity and mortality. Characterised by a strong central government role in surveillance, procurement, and distribution, the market’s performance is tightly coupled with national health priorities and the capacity of domestic biotechnology and pharmaceutical firms. Iran, similar to other Northern Hemisphere countries, experiences annual influenza epidemics during the cold season, predominantly driven by Influenza Type A strains. The demand dynamics are unique, heavily influenced by national self-sufficiency mandates in the face of geopolitical constraints and a concerted effort to modernise diagnostic capabilities within key public health facilities.

________________________________________

Iran Flu Diagnostic and Treatment Market Analysis

Growth Drivers

The annual, predictable nature of the influenza epidemic in the cold seasons, confirmed by a consistent cyclic pattern of reported positive cases, is the foremost systemic growth driver, creating a non-negotiable demand for diagnostics and therapeutics ahead of each surge. The government’s sustained commitment to public health preparedness, as evidenced by its historical investments in the health sector to modernise infrastructure, actively increases demand for sophisticated molecular diagnostics within the Hospital Laboratory network. Furthermore, the established national surveillance systems, which mandate laboratory confirmation of suspected cases, specifically drive demand for the Diagnostics segment, particularly for the more accurate Rapid Molecular Assay kits capable of differentiating influenza types (A and B) and other respiratory viruses, thereby improving patient management, especially in the >=65 Years age group.

Challenges and Opportunities

The primary market obstacle is the consistent challenge of low influenza vaccine uptake across key vulnerable and healthcare-provider groups, which maintains a large susceptible population and structurally inflates peak seasonal demand for both diagnostic testing and acute antiviral treatment. This demand is further stressed by late hospital admissions and delayed laboratory diagnoses, often observed in past outbreaks, which pushes demand toward emergency, high-acuity Therapeutics. The core opportunity lies in the expanding capability of domestic knowledge-based companies to produce molecular diagnostic kits, including those that differentiate influenza from coronaviruses. This domestic production capability directly captures demand by providing cost-effective, locally manufactured kits, circumventing import restrictions and supply chain volatility for Reference Laboratories.

Raw Material and Pricing Analysis

The pricing dynamics for Therapeutics, primarily Oseltamivir, are heavily influenced by the ability of Iranian pharmaceutical firms to manufacture the drug generically, relying either on locally produced Active Pharmaceutical Ingredients (APIs) or imported, cost-sensitive generic APIs. Geopolitical sanctions directly constrain the supply and increase the landed cost of specialised reagents, enzymes, and consumables necessary for high-accuracy Rapid Molecular Assay kits, even for domestic manufacturers like Hana Gene. This external cost pressure translates into higher operational costs for Hospital Laboratories when performing complex molecular tests. Consequently, the MoHME must balance the public health imperative of using gold-standard diagnostics with the inherent financial constraints imposed by the limited availability and price volatility of key imported diagnostic components.

Supply Chain Analysis

The Iran Flu Diagnostic and Treatment Market supply chain operates under the unique and stringent constraints of international sanctions. For high-end Diagnostics (e.g., Rapid Molecular Assay), the supply chain remains dependent on a complex import process for highly specialised instruments, reagents, and master mixes, which introduces procurement friction and logistical delays. The Ministry of Health and Medical Education (MoHME) and its affiliated purchasing bodies, like Heyat Omanaye Arzi, manage the centralised importation and distribution of critical items, creating a single-channel procurement dependency. In the Therapeutics segment, the supply chain is highly domesticated, leveraging the capacity of large Iranian pharmaceutical companies to formulate generic antiviral drugs. This local manufacturing capability buffers the market against external supply shocks but remains vulnerable to the sustained high cost and irregular supply of precursor chemicals and certain APIs.

Government Regulations

________________________________________

In-Depth Segment Analysis

By Offering: Rapid Molecular Assay

The Rapid Molecular Assay segment of the Diagnostics offering is emerging as the critical technology in major urban Hospital Laboratory and Reference Laboratory settings. Unlike traditional, low-sensitivity Rapid Influenza Diagnostic Tests (RIDTs), molecular assays (primarily real-time RT-PCR) provide high sensitivity and specificity, enabling the definitive and rapid identification of influenza Types A and B. The increasing epidemiological focus on H1N1, a severe Type A subtype prevalent in Iran, and the imperative to distinguish influenza from other circulating respiratory viruses drive demand for the multi-pathogen detection capabilities inherent in these molecular kits. Their superior performance, coupled with the government's push for standardised, reliable surveillance data, actively funnels capital expenditure demand toward the acquisition of these advanced technologies and away from less accurate testing methods, particularly for hospitalised patients in the >=65 Years age group, where timely diagnosis dictates favourable treatment outcomes.

By End-User: Hospital Laboratory

The Hospital Laboratory represents the highest-value end-user segment due to its immediate role in acute patient management and severe case surveillance. Demand is structurally driven by the volume of hospitalised patients, particularly high-risk individuals and those with severe respiratory illness, which necessitates immediate, definitive diagnosis. The need for rapid turnaround time to implement appropriate infection control measures and initiate Oseltamivir treatment generates critical demand for on-site diagnostic capacity, often utilising multiplex real-time PCR technologies. These laboratories are also integral to the national surveillance network, requiring standardised, high-quality kits and reagents, thereby making them the primary customers for advanced Rapid Molecular Assay products. The consistent influx of critically ill patients from the >=65 Years age bracket, where the case fatality rate is higher, ensures the prioritisation of diagnostic resource allocation and sustained, high-level demand within this specific end-user category.

________________________________________

Competitive Environment and Analysis

The competitive landscape in the Iranian Flu Diagnostic and Treatment Market is characterised by a dual structure: a limited number of global players whose products are accessible despite sanctions, and a significant and growing cohort of domestic knowledge-based companies. Competition among local firms is focused on rapid technological adaptation and cost-effective, locally-sourced production to capture public procurement contracts.

Pasteur Institute of Iran (IPI)

The Pasteur Institute of Iran holds a strategic and regulatory central position within the market. While not a commercial company in the traditional sense, its role as the National Reference Laboratory and a centre for R&D makes it a formidable entity. IPI actively influences demand for diagnostics by validating and distributing all commercial diagnostic kits (domestic and foreign) through the national network. Its historical and ongoing role in surveillance and response, including the production of vaccines and research into diagnostics, positions it as the definitive standard-setter, channelling demand toward technologies and products that align with its internal protocol and quality assurances.

Hana Gene Company

Hana Gene is a key Iranian knowledge-based company focusing on molecular diagnostic kits. The company's strategic positioning is a direct response to the market imperative for domestic self-sufficiency in high-tech medical products. Hana Gene directly captures demand from the Reference Laboratory and Hospital Laboratory segments by producing molecular diagnostic kits, including those capable of differentiating between influenza A and B, and other concurrent respiratory viruses. This domestic production reduces the market's vulnerability to supply chain disruptions caused by international sanctions, making their products a reliable, preferred option for public health entities requiring a consistent supply.

________________________________________

Recent Market Developments

November 2022: Iranian Scientists Produce Diagnostic Kits to Distinguish Coronavirus from Different Types of Flu

• A knowledge-based company, Hana Gene, announced the production and presentation of laboratory diagnostic kits capable of differentiating between coronavirus and different types of influenza (A and B). This product launch directly addresses the sustained, high-priority demand from Hospital Laboratory and Reference Laboratory segments for effective differential diagnosis tools, improving resource allocation and patient management during periods of co-circulation of these pathogens.

Iran Flu Diagnostic and Treatment Market Segmentation

• By Type of Flu
  • Type A
  • Type B
• By Offering
  • Diagnostics
    • Rapid Influenza Diagnostic Test
    • Rapid Molecular Assay
    • Others
  • Therapeutics
• By Age Group
  • 0-14 Years
  • 15-64 Years
  • >=65 Years
• By End-User
  • Hospital Laboratory
  • Outpatient Clinic
  • Reference Laboratory

Table Of Contents

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

3.4. Porter's Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations

3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. IRAN FLU DIAGNOSTIC AND TREATMENT MARKET BY TYPE OF FLU

5.1. Introduction

5.2. Type A

5.3. Type B

6. IRAN FLU DIAGNOSTIC AND TREATMENT MARKET BY OFFERING

6.1. Introduction

6.2. Diagnostics

6.2.1. Rapid Influenza Diagnostic Test

6.2.2. Rapid Molecular Assay

6.2.3. Others

6.3. Therapeutics

7. IRAN FLU DIAGNOSTIC AND TREATMENT MARKET BY AGE GROUP

7.1. Introduction

7.2. 0-14 Years

7.3. 15-64 Years

7.4. >=65 Years

8. IRAN FLU DIAGNOSTIC AND TREATMENT MARKET BY END-USER

8.1. Introduction

8.2. Hospital Laboratory

8.3. Outpatient Clinic

8.4. Reference Laboratory

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. AryoGen Pharmed.

10.2. CinnaGen.

10.3. Pasteur Institute of Iran.

10.4. Mahban Darou (Mahbaflu).

10.5. Nafas Zist Pharmed.

10.6. Pooyesh Darou.

10.7. ProGnosis Biotech.

10.8. Roche.

10.9. Hana Gene

11. APPENDIX

11.1. Currency

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology

11.6. Abbreviations

LIST OF FIGURES

LIST OF TABLES

Companies Profiled

AryoGen Pharmed

CinnaGen

Pasteur Institute of Iran

Mahban Darou (Mahbaflu)

Nafas Zist Pharmed

Pooyesh Darou

ProGnosis Biotech

Roche

Hana Gene

Related Reports